These Proceedings are the outcome of the First Tarbox Parkinson''s Disease Symposium held October 14-16, 1976, at the South Park Inn in Lubbock, Texas. The Symposium was sponsored by the Department of Pharmacology and Therapeutics and the Tarbox Parkinson''s Disease In­ stitute of the Texas Tech University School of Medicine at Lubbock. The Tarbox Parkinson''s Disease Institute was established in 1973 with funds appropriated by the State of Texas and is dedicated to re­ search, patient care, and educational activities related to Parkinson''s disease. The Institute is named after Mr. Elmer L. Tarbox, who recently served the Lubbock area as a Representative to the Texas Legislature, and is himself a parkinsonian patient. Mr. and Mrs. Tarbox attended the Symposium as honored guests. The First Tarbox Parkinson''s Disease Symposium was devoted to both basic and clinical aspects of Parkinson''s disease, with an emphasis on discussion of drug therapy. This discussion focused not only on readily available drugs such as levodopa, but also on new investigational drugs such as bromocriptine. Thanks are especially due to Thelma Saunders and the office staff of the Department of Pharmacology and Therapeutics, Texas Tech Univer­ sity School of Medicine, for their excellent service in producing camera-ready copy for the Publisher. Thanks are also due to Fathy S. Messiha, Program Chairman, to the other committee members, and to the staff of the Office of Continuing Education and Faculty Development. The Symposium could not have succeeded without their help.

These Proceedings are the outcome of the First Tarbox Parkinson''s Disease Symposium held October 14-16, 1976, at the South Park Inn in Lubbock, Texas. The Symposium was sponsored by the Department of Pharmacology and Therapeutics and the Tarbox Parkinson''s Disease In­ stitute of the Texas Tech University School of Medicine at Lubbock. The Tarbox Parkinson''s Disease Institute was established in 1973 with funds appropriated by the State of Texas and is dedicated to re­ search, patient care, and educational activities related to Parkinson''s disease. The Institute is named after Mr. Elmer L. Tarbox, who recently served the Lubbock area as a Representative to the Texas Legislature, and is himself a parkinsonian patient. Mr. and Mrs. Tarbox attended the Symposium as honored guests. The First Tarbox Parkinson''s Disease Symposium was devoted to both basic and clinical aspects of Parkinson''s disease, with an emphasis on discussion of drug therapy. This discussion focused not only on readily available drugs such as levodopa, but also on new investigational drugs such as bromocriptine. Thanks are especially due to Thelma Saunders and the office staff of the Department of Pharmacology and Therapeutics, Texas Tech Univer­ sity School of Medicine, for their excellent service in producing camera-ready copy for the Publisher. Thanks are also due to Fathy S. Messiha, Program Chairman, to the other committee members, and to the staff of the Office of Continuing Education and Faculty Development. The Symposium could not have succeeded without their help.

These Proceedings are the outcome of the First Tarbox Parkinson''s Disease Symposium held October 14-16, 1976, at the South Park Inn in Lubbock, Texas. The Symposium was sponsored by the Department of Pharmacology and Therapeutics and the Tarbox Parkinson''s Disease In­ stitute of the Texas Tech University School of Medicine at Lubbock. The Tarbox Parkinson''s Disease Institute was established in 1973 with funds appropriated by the State of Texas and is dedicated to re­ search, patient care, and educational activities related to Parkinson''s disease. The Institute is named after Mr. Elmer L. Tarbox, who recently served the Lubbock area as a Representative to the Texas Legislature, and is himself a parkinsonian patient. Mr. and Mrs. Tarbox attended the Symposium as honored guests. The First Tarbox Parkinson''s Disease Symposium was devoted to both basic and clinical aspects of Parkinson''s disease, with an emphasis on discussion of drug therapy. This discussion focused not only on readily available drugs such as levodopa, but also on new investigational drugs such as bromocriptine. Thanks are especially due to Thelma Saunders and the office staff of the Department of Pharmacology and Therapeutics, Texas Tech Univer­ sity School of Medicine, for their excellent service in producing camera-ready copy for the Publisher. Thanks are also due to Fathy S. Messiha, Program Chairman, to the other committee members, and to the staff of the Office of Continuing Education and Faculty Development. The Symposium could not have succeeded without their help.